There are aproximately 25 laboratories at the MassGeneral Institute for Neurodegenerative Disease. Led by physician-scientists, certain labs collaborate and share resources on key projects to speed up the pace of discovering new treatments, and one day, we trust, find cures.
The Albers’s Laboratory uses the olfactory system of mice and humans to elucidate early pathologic events of neurodegeneration.
Brian Bacskai's laboratory uses sophisticated optical techniques to address fundamental questions in Alzheimer's disease research.
The research goal of Dr. Berezovska's lab is to study the cellular and molecular mechanisms of Alzheimer's disease pathology.
MIND Informatics develops and applies integrative computational methods in biomedical and brain research, working with leading clinicians and researchers to understand and cure neurological disorders.
Marian M. DiFiglia, PhD, is investigating the role of the HD mutation in the molecular and cellular events leading to neurodegeneration.
My laboratory is interested in the development and characterization of animal models of human neurodegenerative diseases, particularly Cerebral amyloid angiopathy (CAA), Alzheimer and Parkinson diseases.
Dr. Gomez-Isla investigates the neurobiology of normal aging, Alzheimers, and other dementias.
Led by Dr. Hersch, the Laboratory investigates Huntington’s disease using transgenic mouse models and human brain tissue. Research also includes HD clinical trials.
The Hyman lab focuses on research in neural system failure underlying cognitive loss in Alzheimer’s disease.
The Kazantsev lab is focused on discovering therapeutic agents for Huntington's and Parkinson's diseases using high throughput screening, rational drug design, and medicinal chemistry lead optimization.
Molecular research of neurodegeneration in Alzheimer’s disease (AD) focused on identifying cellular pathways regulating the generation of the toxic beta-amyloid protein (Abeta).
The Krainc laboratory utilizes molecular and genetic approaches to identify key molecular targets for the development of neuroprotective therapies for Huntington’s, Parkinson’s and related neurodegenerative diseases.
Dr. Robert Moir's research focuses on the biochemical and cellular mechanisms involved in neurodegeneration in Alzheimer's disease and aging.
The laboratory focuses on identifying epigenetic alterations that regulate gene expression in brain disorders, and investigates whether these alterations are heritable across multiple generations.
The Schwarzschild lab targets three purines—adenosine, caffeine and urate—in pursuit of improved therapy for Parkinson’s and related neurodegenerative diseases.
Bakhos Tannous, PhD – Research focus in molecular Imaging, gene transfer technologies and high throughput screening aiming at finding novel therapeutics against brain tumors.
Dr. Rudolph Tanzi is carrying out genome-wide association screens to identify novel genes associated with AD and autism spectrum disorders.
Dr. Young’s laboratory is examining the role of the protein alpha-synuclein, which plays a key role in the death of dopamine-producing brain cells in the Parkinson’s disease and other diseases with similar symptoms.
There are no results found in this category.
Use the search box in the upper right corner of the page to find related content.